hepatitis C immune globulin

Hepatitis C immune globulin is a **purified human polyclonal antibody preparation** derived from pooled plasma of donors chronically infected with hepatitis C virus. It is developed to **prevent recurrence of hepatitis C infection** in liver transplant recipients by neutralizing circulating hepatitis C virions. The main investigational product, Civacir, is formulated as a 10% protein solution and is undergoing phase III clinical trials for prevention of HCV reinfection post-liver transplantation. The drug broadly neutralizes diverse HCV variants, including those resistant to direct-acting antivirals, through a mixture of anti-HCV antibodies targeting viral envelope proteins[1][2]. It is distinct from standard intravenous immune globulin by being specifically enriched for anti-HCV activity. Civacir is manufactured using improved processes over earlier 5% formulations, involving rigorous viral inactivation and fractionation steps[1].

Brand names

Civacir

Other names

hepatitis C immune globulin (human)